^
    Back
    Association details:
    Biomarker:BTK expression + BCL2 expression + MYC expression
    Cancer:Diffuse Large B Cell Lymphoma
    Regimen: (cyclophosphamide + doxorubicin hydrochloride + prednisone + Rituxan (rituximab) + vincristine)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Anticancer Res
    Title:

    Clinicopathologic and Prognostic Significance of Bruton’s Tyrosine Kinase Expression in Diffuse Large B-Cell Lymphoma

    Published date:
    11/01/2021
    Excerpt:
    Moreover, high risk, defined as co-expression of BTK and either or both BCL2/MYC, independently predicted shorter progression-free survival in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) (all R-CHOP-treated patients: hazard ratio=2.565, p=0.044; R-CHOP-treated non-GCB subgroup: HR=3.833, p=0.019)....BTK expression may be utilized to stratify risk in patients with DLBCL.
    DOI:
    10.21873/anticanres.15384